Navigation Links
EpiCept Reports Second Quarter 2013 Operating and Financial Results
Date:7/31/2013

ture.  In July 2013, EpiCept and MidCap executed a Second Amendment to the Loan and Security Agreement in which the parties agreed that interest payments will continue to be made monthly and one half of the cash escrow will be returned to EpiCept upon the favorable stockholder vote to approve the final conditions to the closing of the merger.  Any past defaults under the loan agreement have been waived and principal payments on the existing loan will begin September 1, 2013 if the agreement restructuring the loan has not been completed.

Product PipelineFollowing the completion of the merger, IPI's product portfolio will consist of the following products:

  • Bertilimumab - a first in class monoclonal antibody (mAb) that targets eotaxin-1, a small protein that attracts and activates several sub-classes of immune cells, which are white blood cells that play a role in the development of several inflammatory diseases, including Crohn's Disease, ulcerative colitis, severe asthma and bullous pemphigoid, a dermatological auto-immune orphan condition with high unmet medical need. Eotaxin-1 has been shown to correlate with the severity of those diseases, which allows for selection of patients based on eotaxin-1 levels, a major step toward treatment personalization. Immune is currently initiating a multi-national Phase II trial of bertilimumab for the treatment of ulcerative colitis, and plans to initiate in late 2013 a Phase II trial for the treatment of bullous pemphigoid.  Data from these trials is expected to report during 2014.
  • NanomAbs -  an antibody drug conjugate (ADC) platform designed to deliver cancer drugs specifically to tumor cells thereby improving efficacy and reducing off-target undesirable effects.  Immune intends to continue development of its own candidates as well as to enter into partnerships where it will incorporate the partner's chemotherapeutic drug into the NanomAbs and/or power the partner's an
    '/>"/>

  • SOURCE EpiCept Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    6. Pharmasset Reports Fiscal Year End 2011 Financial Results
    7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
    (Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
    (Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
    (Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
    Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
    ... consecutive year, the City of Madison received recognition ... in the country. , ,In its 2006 Digital Survey ... research and advisory institute on information technology and best practices ... top user of technology in its 125,000-249,999 population category. Madison ...
    ... Wauwatosa, Wis. - A Medical College of Wisconsin ... work to isolate, grow, and identify a new type of ... to have the potential for diversification. , ,The readily-available adult ... , ,According to the Medical College, the team recently ...
    ... symposium presented last week at the Milwaukee School ... impressive as their messages. , ,Mary Glass of ... is championing the issue for Milwaukee neighborhoods, delivered a ... everyone the critical opportunity to take advantage of what ...
    Cached Biology Technology:Medical College team seeks stem cell patent 2Medical College team seeks stem cell patent 3Handicapping Milwaukee's wireless initiative 2Handicapping Milwaukee's wireless initiative 3Handicapping Milwaukee's wireless initiative 4Handicapping Milwaukee's wireless initiative 5
    (Date:10/15/2014)... to bacterial pneumonia in female mice to an enzyme ... are naturally more resistant to respiratory infections than males. ... increased resistance to bacterial pneumonia in female mice is ... They also show that this enzyme is ultimately activated ... , The team, lead by Professor Lester Kobzik at ...
    (Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology , ... announced the availability of the VeriLook Surveillance ... 3.0 provides real-time biometric face identification using live ... surveillance cameras. The new version not only identifies ... people from objects while they are moving through ...
    (Date:10/14/2014)... 14, 2014)—It,s been millions of years since T. ... led by Ohio University scientists is breathing life back ... through dinosaur snouts. The research has important implications for ... but to enhance the sense of smell and cool ... said Ohio University doctoral student Jason Bourke, lead author ...
    Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
    ... College students often spend their free time thinking about ... taking it to the next level. They,re using genetic ... in wine that,s been shown to reduce cancer and ... be entered in the International Genetically Engineered Machine (iGEM) ...
    ... Infectious Diseases (NAID), one of the National Institutes of ... Washington (UW) to use systems biology approaches to comprehensively ... networks that are induced or altered during the course ... program will be led by Dr. Michael Katze, UW ...
    ... October 16, 2008 Two new articles examine the ... health disparities. The studies, published in American Journal ... of hypertension and cardiovascular disease present in African Americans ... that these low birth weights may be a result ...
    Cached Biology News:Better beer: College team creating anticancer brew 2Better beer: College team creating anticancer brew 3NIAID funds studies of how SARS and bird flu evade antiviral responses 2Racial disparities in cardiovascular health linked to birth weight, slavery 2Racial disparities in cardiovascular health linked to birth weight, slavery 3
    ... CL3 series is designed to enhance ... clinical applications at a reasonable cost. ... quick connect rotors and various biocontainment ... interface allows you to control and ...
    PP2B-Abeta (C-20)...
    DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
    ... a fully licensed, high throughput, water bath thermal ... to 24 microplates. This equates to 9,216 reactions ... A robotic arm rapidly transfers a basket of ... ramping times that are considerably faster than those ...
    Biology Products: